CD38 and cancer: Both TNFRSF12A/TWEAK pair (Whitsett et al., 2014) and CD38, along with its interaction partner CD31 (Malavasi et al., 2008) are involved in multiple cancers, including NSCLC, where they contribute to escape from PD-1/PD-L1 blockade (Chen et al., 2018; Konen et al., 2019) and cytotoxic therapy (Whitsett et al., 2014).